/Moderna%20Inc%20meds-by%20Ascannio%20via%20Shutterstock.jpg)
Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that provides messenger RNA medicines worldwide. With a market cap of $10.6 billion, the company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development.
Companies valued at $10 billion or more are generally described as "large-cap stocks", and Moderna fits this criterion perfectly. The company is also expanding its pipeline to include treatments for cancer, rare diseases, and autoimmune conditions, reflecting its broader commitment to revolutionizing medicine through cutting-edge mRNA science.